Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD011 for hyperphagia-related behavior in Prader-Willi syndrome
2021-005331-23Phase 2Terminated
- Sponsor
- Radius Pharmaceuticals, Inc.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing RAD011 with Placebo (2 arms). Primary endpoint: Change in HQ-CT score. Started Apr 2022; status: terminated.
02
Drugs
RAD011
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2021-005331-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005331-23.